PE20181804A1 - Derivados de aminotiazol utiles como agentes antiviricos - Google Patents

Derivados de aminotiazol utiles como agentes antiviricos

Info

Publication number
PE20181804A1
PE20181804A1 PE2018001949A PE2018001949A PE20181804A1 PE 20181804 A1 PE20181804 A1 PE 20181804A1 PE 2018001949 A PE2018001949 A PE 2018001949A PE 2018001949 A PE2018001949 A PE 2018001949A PE 20181804 A1 PE20181804 A1 PE 20181804A1
Authority
PE
Peru
Prior art keywords
methyl
aminotiazole
useful
antiviric
derivatives
Prior art date
Application number
PE2018001949A
Other languages
English (en)
Inventor
Gerald Kleymann
Christian Gege
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55701658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181804(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of PE20181804A1 publication Critical patent/PE20181804A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINOTIAZOL DE FORMULA (I) DONDE X, R1, R4, R5, R5', R6, R6', R7 Y n SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 2-(2',5'-DIFLUORO-[1,1-BIFENIL]-4-IL)-N-(5-(N-(4-METOXIBENCIL)SULFINAMOIL)-4-METILTIAZOL-2-IL)-N-METILACETAMIDA; 2-[4-(2,5-DIFLUOROFENIL)FENIL]-N-[5-[[(4-METOXIBENCIL)AMINO]SULFONIMIDOIL]-4-METIL-TIAZOL-2-IL]-N-METIL-ACETAMIDA; 2-(2',5'-DIFLUORO-[1,1'-BIFENIL]-4-IL)-N-METIL-N-(4-METIL-5-SULFAMIMIDOILTIAZOL-2-IL)ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ANHIDRASA CARBONICA II SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES VIRICAS COMO LAS CAUSADAS POR EL VIRUS DEL HERPES SIMPLEX
PE2018001949A 2016-04-06 2017-04-05 Derivados de aminotiazol utiles como agentes antiviricos PE20181804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16000787 2016-04-06

Publications (1)

Publication Number Publication Date
PE20181804A1 true PE20181804A1 (es) 2018-11-19

Family

ID=55701658

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001949A PE20181804A1 (es) 2016-04-06 2017-04-05 Derivados de aminotiazol utiles como agentes antiviricos

Country Status (27)

Country Link
US (2) US10590094B2 (es)
EP (1) EP3440063B1 (es)
JP (1) JP6918823B2 (es)
KR (1) KR102354411B1 (es)
CN (1) CN109071473B (es)
AR (1) AR108175A1 (es)
AU (1) AU2017245679B2 (es)
BR (1) BR112018070448A2 (es)
CA (1) CA3018026A1 (es)
CL (1) CL2018002811A1 (es)
CO (1) CO2018010689A2 (es)
CR (1) CR20180482A (es)
CU (1) CU24519B1 (es)
EA (1) EA035401B1 (es)
EC (1) ECSP18074962A (es)
ES (1) ES2834051T3 (es)
GE (1) GEP20207128B (es)
IL (1) IL261421A (es)
MX (2) MX2018012116A (es)
MY (1) MY198018A (es)
PE (1) PE20181804A1 (es)
PH (1) PH12018501979A1 (es)
SV (1) SV2018005760A (es)
TW (1) TWI706940B (es)
UA (1) UA123734C2 (es)
UY (1) UY37193A (es)
WO (1) WO2017174640A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107118207B (zh) * 2017-05-22 2020-10-02 苏州东南药业股份有限公司 一类cdk抑制剂的制备方法
SI3692039T1 (sl) * 2017-10-05 2023-04-28 Innovative Molecules Gmbh Enantomeri substituiranih tiazolov kot protivirusne spojine
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN116783171A (zh) 2020-10-29 2023-09-19 创新分子股份有限公司 作为抗病毒化合物的氘化氨基噻唑化合物
TW202337444A (zh) 2022-01-17 2023-10-01 德商創新分子有限責任公司 解旋酶引子酶抑制劑的固體結晶形式及其製備方法
WO2024049760A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
ATE227279T1 (de) 1995-12-29 2002-11-15 Boehringer Ingelheim Pharma Phenyl thiazol derivate mit antiherpesvirus eigenschaften
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
WO1999047507A2 (en) 1998-03-19 1999-09-23 Pharmacia & Upjohn Company 1,3,4-thiadiazoles useful for the treatment of cmv infections
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
DE50008597D1 (de) 1999-03-08 2004-12-16 Bayer Healthcare Ag Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
AU2000259734A1 (en) 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129715A1 (de) 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2635124A4 (en) * 2010-11-01 2014-04-16 Romark Lab Lc ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
CR20180482A (es) 2019-04-09
UA123734C2 (uk) 2021-05-26
TWI706940B (zh) 2020-10-11
EP3440063B1 (en) 2020-08-05
ES2834051T3 (es) 2021-06-16
EA201892246A1 (ru) 2019-04-30
CO2018010689A2 (es) 2018-10-22
US20190112285A1 (en) 2019-04-18
UY37193A (es) 2017-11-30
CN109071473B (zh) 2022-12-09
IL261421A (en) 2018-10-31
MX2020005079A (es) 2020-08-13
EA035401B1 (ru) 2020-06-08
JP2019515883A (ja) 2019-06-13
AU2017245679B2 (en) 2021-07-01
KR102354411B1 (ko) 2022-01-21
CU20180124A7 (es) 2019-04-04
JP6918823B2 (ja) 2021-08-11
CA3018026A1 (en) 2017-10-12
AU2017245679A1 (en) 2018-10-04
PH12018501979A1 (en) 2019-07-01
GEP20207128B (en) 2020-07-10
MX2018012116A (es) 2019-05-23
SV2018005760A (es) 2019-03-08
MY198018A (en) 2023-07-26
BR112018070448A2 (pt) 2019-02-05
AR108175A1 (es) 2018-07-25
CU24519B1 (es) 2021-06-08
KR20180132674A (ko) 2018-12-12
CN109071473A (zh) 2018-12-21
CL2018002811A1 (es) 2019-02-08
US20200148652A1 (en) 2020-05-14
ECSP18074962A (es) 2018-11-30
TW201738217A (zh) 2017-11-01
EP3440063A1 (en) 2019-02-13
WO2017174640A1 (en) 2017-10-12
US10590094B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
PE20181804A1 (es) Derivados de aminotiazol utiles como agentes antiviricos
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20140038A1 (es) Compuestos antivirales
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20200177A1 (es) Inhibidores de pd-1/pd-l1
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20191406A1 (es) N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
PE20141599A1 (es) Derivados de los nucleosidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicacion del rna del vhc
PE20141375A1 (es) Activadores de glucoquinasa
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20160891A1 (es) Moduladores de ror gamma (rory)
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20171737A1 (es) Derivados de quinazolinona biciclicos
PE20210373A1 (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos
PE20120517A1 (es) Inhibidores del virus de la hepatitis c
PE20120013A1 (es) Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20090641A1 (es) Amidas heterociclicas
PE20131377A1 (es) Triazina-oxadiazoles
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS